Patents by Inventor Andrew Bogdan

Andrew Bogdan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BROMODOMAIN INHIBITORS
    Publication number: 20250145587
    Abstract: The present invention provides for compounds of formula (I) wherein R1, Y, X1, X2, R2, R3, R4, R5, R6, and m have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising compounds of formula (I).
    Type: Application
    Filed: June 4, 2024
    Publication date: May 8, 2025
    Inventors: Andrew Bogdan, Steven Fidanze, Keith McDaniel, John Pratt, Le Wang
  • PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20250122160
    Abstract: Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.
    Type: Application
    Filed: April 26, 2024
    Publication date: April 17, 2025
    Inventors: Philip R. Kym, Jennifer M. Frost, Christos Economou, Andrew Bogdan, Stacy Fosu, Zhaoming Xiong, Spencer O. Scholz, Eric Allan Voight, Elliot P. Farney, Mark A. Matulenko, Matthew J. O'Connor, Christina Baumgartner, Qingwei Zhang, Reza Shiroodi, Jason R. Abbott, Geoff T. Halvorsen
  • PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20250042894
    Abstract: The present invention provides for compounds of Formula (I) wherein R1, has any of the values defined herein, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of non-small cell lung cancer.
    Type: Application
    Filed: November 10, 2022
    Publication date: February 6, 2025
    Inventors: Andrew Bogdan, Christos Economou, Jennifer M. Frost, Philip R. Kym, Spencer O. Scholz, Zhaoming Xiong
  • PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20250019374
    Abstract: The present invention provides for compounds of Formula (I) (I); wherein R2, X, and Z have any of the values defined herein, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of non-small cell lung cancer.
    Type: Application
    Filed: November 10, 2022
    Publication date: January 16, 2025
    Inventors: Andrew Bogdan, Elliot P. Farney, Jennifer M. Frost, Philip R. Kym, Zhaoming Xiong, Naomi Anne Barton, Claire Anne Marie Cariou-Mumford, Christopher Patrick McMahon, Giuseppe Nano
  • Pyrrolidine Main Protease Inhibitors as Antiviral Agents
    Publication number: 20240158368
    Abstract: Pyrrolidine main protease inhibitors are described that are effective as antiviral compounds.
    Type: Application
    Filed: October 12, 2023
    Publication date: May 16, 2024
    Applicant: AbbVie Inc.
    Inventors: David A. Degoey, Michael R. Schrimpf, David J. Hardee, Jacob Ludwig, Eric R. Miller, Timothy R. Hodges, Alberto Munoz, Sarah J. Perlmutter, Huan-Qiu X. Li, Alvin Jang, Elizabeth L. Noey, Gregory A. Gfesser, Edgars Jecs, Robert G. Schmidt, Justin D. Dietrich, Xenia B. Searle, Boguslaw P. Nocek, Andrew Bogdan
  • Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
    Publication number: 20240043386
    Abstract: The present invention provides for compounds of Formula (I) wherein R1 has any of the values defined in the specification, and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
    Type: Application
    Filed: October 10, 2023
    Publication date: February 8, 2024
    Inventors: Andrew Bogdan, David J. Hardee, Timothy R. Hodges, Henry Korman, Huan-Qiu Li, Michael R. Schrimpf
  • Bromodomain Inhibitors
    Publication number: 20230101559
    Abstract: The present invention provides for compounds of formula (I) wherein R1, Y, X1, X2, R2, R3, R4, R5, R6, and m have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising compounds of formula (I).
    Type: Application
    Filed: March 11, 2022
    Publication date: March 30, 2023
    Inventors: Andrew Bogdan, Steven Fidanze, Keith McDaniel, John Pratt, Le Wang
  • PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20230019236
    Abstract: Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.
    Type: Application
    Filed: June 16, 2022
    Publication date: January 19, 2023
    Inventors: Elliot P. Farney, Reza Shiroodi, Zhaoming Xiong, Qingwei Zhang, Matthew J. O'Connor, Geoff T. Halvorsen, Hongyu Zhao, Christina Baumgartner, Jennifer M. Frost, Philip R. Kym, Jason R. Abbott, Andrew Bogdan, Christos Economou, Xueqing Wang
  • Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
    Publication number: 20220213041
    Abstract: The present invention provides for compounds of Formula (I) wherein R1 has any of the values defined in the specification, and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
    Type: Application
    Filed: December 17, 2021
    Publication date: July 7, 2022
    Applicant: AbbVie Global Enterprises Ltd.
    Inventors: Andrew Bogdan, David J. Hardee, Timothy R. Hodges, Henry Korman, Huan-Qiu Li, Michael R. Schrimpf
  • Bromodomain Inhibitors
    Publication number: 20210253551
    Abstract: The present invention provides for compounds of formula (I) wherein R1, Y, X1, X2, R2, R3, R4, R5, R6, and m have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising compounds of formula (I).
    Type: Application
    Filed: November 20, 2020
    Publication date: August 19, 2021
    Inventors: Andrew Bogdan, Steven Fidanze, Keith McDaniel, John Pratt, Le Wang
  • Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
    Publication number: 20210238159
    Abstract: The invention discloses compounds of Formula (I), wherein A1, R1, R2, R3, R4, and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
    Type: Application
    Filed: April 15, 2021
    Publication date: August 5, 2021
    Inventors: Robert J. Altenbach, Andrew Bogdan, Sylvain Couty, Nicolas Desroy, Gregory A. Gfesser, Christopher Gaëtan Housseman, Philip R. Kym, Bo Liu, Thi Thu Trang Mai, Karine Fabienne Malagu, Nuria Merayo Merayo, Olivier Laurent Picolet, Mathieu Rafaël Pizzonero, Xenia B. Searle, Steven Emiel Van der Plas, Xueqing Wang, Ming C. Yeung
  • Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
    Patent number: 10988454
    Abstract: The invention discloses compounds of Formula (I), wherein A1, R1, R2, R3, R4, and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
    Type: Grant
    Filed: September 12, 2018
    Date of Patent: April 27, 2021
    Assignees: AbbVie Overseas S.à.r.l., Galapagos NV
    Inventors: Robert J. Altenbach, Andrew Bogdan, Sylvain Couty, Nicolas Desroy, Gregory A. Gfesser, Christopher Gaëtan Housseman, Philip R. Kym, Bo Liu, Thi Thu Trang Mai, Karine Fabienne Malagu, Nuria Merayo Merayo, Olivier Laurent Picolet, Mathieu Rafaël Pizzonero, Xenia B. Searle, Steven Emiel Van der Plas, Xueqing Wang, Ming C. Yeung
  • Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
    Patent number: 10981890
    Abstract: The invention discloses compounds of Formula (I), wherein A1, R1, R2, R3, R4, and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
    Type: Grant
    Filed: May 19, 2020
    Date of Patent: April 20, 2021
    Assignees: AbbVie Overseas S.à.r.l., Galapagos NV
    Inventors: Robert J. Altenbach, Andrew Bogdan, Sylvain Couty, Nicolas Desroy, Gregory A. Gfesser, Christopher Gaëtan Housseman, Philip R. Kym, Bo Liu, Thi Thu Trang Mai, Karine Fabienne Malagu, Nuria Merayo Merayo, Olivier Laurent Picolet, Mathieu Rafaël Pizzonero, Xenia B. Searle, Steven Emiel Van der Plas, Xueqing Wang, Ming C. Yeung
  • TETRACYCLIC BROMODOMAIN INHIBITORS
    Publication number: 20210070756
    Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R6, Y1, Y2, Y3, A1, A2, A3, and A4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).
    Type: Application
    Filed: November 16, 2020
    Publication date: March 11, 2021
    Inventors: Steven D. Fidanze, Dachun Liu, Robert A. Mantei, Keith F. McDaniel, John Pratt, George S. Sheppard, Le Wang, Andrew Bogdan, James H. Holms, Justin D. Dietrich, Jasmina Marjanovic, Lisa A. Hasvold, Yujia Dai
  • Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
    Patent number: 10844042
    Abstract: The invention discloses compounds of Formula (I), wherein A1, R1, R2, R3, R4, and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
    Type: Grant
    Filed: May 19, 2020
    Date of Patent: November 24, 2020
    Assignees: AbbVie Overseas S.à.r.l., Galapagos NV
    Inventors: Robert J. Altenbach, Andrew Bogdan, Sylvain Couty, Nicolas Desroy, Gregory A. Gfesser, Christopher Gaëtan Housseman, Philip R. Kym, Bo Liu, Thi Thu Trang Mai, Karine Fabienne Malagu, Nuria Merayo Merayo, Olivier Laurent Picolet, Mathieu Rafaël Pizzonero, Xenia B. Searle, Steven Emiel Van der Plas, Xueqing Wang, Ming C. Yeung
  • Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
    Patent number: 10844041
    Abstract: The invention discloses compounds of Formula (I), wherein A1, R1, R2, R3, R4, and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
    Type: Grant
    Filed: May 19, 2020
    Date of Patent: November 24, 2020
    Assignees: AbbVie Overseas S.à.r.l., Galapagos NV
    Inventors: Robert J. Altenbach, Andrew Bogdan, Sylvain Couty, Nicolas Desroy, Gregory A. Gfesser, Christopher Gaëtan Housseman, Philip R. Kym, Bo Liu, Thi Thu Trang Mai, Karine Fabienne Malagu, Nuria Merayo Merayo, Olivier Laurent Picolet, Mathieu Rafaël Pizzonero, Xenia B. Searle, Steven Emiel Van der Plas, Xueqing Wang, Ming C. Yeung
  • Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
    Patent number: 10829473
    Abstract: The invention discloses compounds of Formula (I), wherein A1, R1, R2, R3, R4, and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
    Type: Grant
    Filed: May 19, 2020
    Date of Patent: November 10, 2020
    Assignees: AbbVie Overseas S.à.r.l., Galapagos NV
    Inventors: Robert J. Altenbach, Andrew Bogdan, Sylvain Couty, Nicolas Desroy, Gregory A. Gfesser, Christopher Gaëtan Housseman, Philip R. Kym, Bo Liu, Thi Thu Trang Mai, Karine Fabienne Malagu, Nuria Merayo Merayo, Olivier Laurent Picolet, Mathieu Rafaël Pizzonero, Xenia B. Searle, Steven Emiel Van der Plas, Xueqing Wang, Ming C. Yeung
  • TETRACYCLIC BROMODOMAIN INHIBITORS
    Publication number: 20200291027
    Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R6, Y1, Y2, Y3, A1, A2, A3, and A4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).
    Type: Application
    Filed: March 23, 2020
    Publication date: September 17, 2020
    Inventors: Steven D. Fidanze, Dachun Liu, Robert A. Mantei, Keith F. McDaniel, John Pratt, George S. Sheppard, Le Wang, Andrew Bogdan, James H. Holms, Justin D. Dietrich, Jasmina Marjanovic, Lisa A. Hasvold, Yujia Dai
  • Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
    Publication number: 20200277273
    Abstract: The invention discloses compounds of Formula (I), wherein A1, R1, R2, R3, R4, and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
    Type: Application
    Filed: May 19, 2020
    Publication date: September 3, 2020
    Inventors: Robert J. Altenbach, Andrew Bogdan, Sylvain Couty, Nicolas Desroy, Gregory A. Gfesser, Christopher Gaëtan Housseman, Philip R. Kym, Bo Liu, Thi Thu Trang Mai, Karine Fabienne Malagu, Nuria Merayo Merayo, Olivier Laurent Picolet, Mathieu Rafaël Pizzonero, Xenia B. Searle, Steven Emiel Van der Plas, Xueqing Wang, Ming C. Yeung
  • MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE
    Publication number: 20200277275
    Abstract: The invention discloses compounds of Formula (I), wherein A1, R1, R2, R3, R4, and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
    Type: Application
    Filed: May 19, 2020
    Publication date: September 3, 2020
    Inventors: Robert J. Altenbach, Andrew Bogdan, Sylvain Couty, Nicolas Desroy, Gregory A. Gfesser, Christopher Gaëtan Housseman, Philip R. Kym, Bo Liu, Thi Thu Trang Mai, Karine Fabienne Malagu, Nuria Merayo Merayo, Olivier Laurent Picolet, Mathieu Rafaël Pizzonero, Xenia B. Searle, Steven Emiel Van der Plas, Xueqing Wang, Ming C. Yeung